2seventy bio, Inc. (NASDAQ:TSVT) CEO William D. Baird III Sells 5,092 Shares of Stock

2seventy bio, Inc. (NASDAQ:TSVT) CEO William D. Baird III sold 5,092 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $4.95, for a total transaction of $25,205.40. Following the transaction, the chief executive officer now owns 1,121,034 shares of the company’s stock, valued at $5,549,118.30. This trade represents a 0.45 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

2seventy bio Price Performance

TSVT stock opened at $4.96 on Thursday. The company has a market capitalization of $255.88 million, a PE ratio of -2.67 and a beta of 1.73. The firm’s 50-day moving average is $2.85 and its 200 day moving average is $3.69. 2seventy bio, Inc. has a 12 month low of $2.29 and a 12 month high of $5.99.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Erste Asset Management GmbH purchased a new position in 2seventy bio during the 3rd quarter valued at about $25,000. China Universal Asset Management Co. Ltd. purchased a new position in 2seventy bio during the 4th quarter valued at about $32,000. Readystate Asset Management LP purchased a new position in 2seventy bio during the 3rd quarter valued at about $53,000. BNP Paribas Financial Markets purchased a new position in 2seventy bio during the 4th quarter valued at about $35,000. Finally, GSA Capital Partners LLP purchased a new position in 2seventy bio during the 3rd quarter valued at about $64,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on TSVT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of 2seventy bio in a research report on Friday, March 7th. Morgan Stanley lowered their target price on shares of 2seventy bio from $6.00 to $5.00 and set an “equal weight” rating for the company in a report on Friday, March 14th. Leerink Partners restated a “market perform” rating and issued a $5.00 target price (down previously from $9.00) on shares of 2seventy bio in a report on Tuesday, March 11th. Finally, Leerink Partnrs downgraded shares of 2seventy bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, 2seventy bio currently has a consensus rating of “Hold” and an average price target of $6.67.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.